MARKET

ALGS

ALGS

Aligos Therapeutics, Inc.
NASDAQ
4.070
-0.440
-9.76%
After Hours: 4.070 0 0.00% 19:30 11/06 EST
OPEN
4.440
PREV CLOSE
4.510
HIGH
4.855
LOW
4.000
VOLUME
101.67K
TURNOVER
--
52 WEEK HIGH
13.69
52 WEEK LOW
3.980
MARKET CAP
25.42M
P/E (TTM)
-0.5565
1D
5D
1M
3M
1Y
5Y
1D
Aligos Therapeutics, Inc. Reports Third Quarter 2026 Financial Results
NASDAQ · 1d ago
Aligos Therapeutics GAAP EPS of -$2.09 beats by $0.19, revenue of $2.83M misses by $2.71M
Seeking Alpha · 1d ago
Aligos Therapeutics Q3 EPS $(2.09) Beats $(2.28) Estimate, Sales $2.830M Miss $5.543M Estimate
Benzinga · 1d ago
Aligos Therapeutics reports Q3 EPS ($2.09), consensus ($2.53)
TipRanks · 1d ago
*Aligos Therapeutics: Runway To Fund Planned Operations Into 1Q 2027 >ALGS
Dow Jones · 2d ago
*Aligos Therapeutics 3Q Loss $21.9M >ALGS
Dow Jones · 2d ago
*Aligos Therapeutics 3Q Loss/Shr $2.09 >ALGS
Dow Jones · 2d ago
Press Release: Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Dow Jones · 2d ago
More
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.

Webull offers Aligos Therapeutics Inc stock information, including NASDAQ: ALGS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALGS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALGS stock methods without spending real money on the virtual paper trading platform.